MGF (Mechano Growth Factor) vs Leuprolide
Side-by-side comparison of key properties, dosing, and research.
Anabolic & IGF
MGF (Mechano Growth Factor)Sexual Health & Libido
Leuprolide- Summary
- MGF (Mechano Growth Factor) is a splice variant of IGF-1 that is locally produced in muscle tissue in response to mechanical damage from exercise. It activates muscle satellite cells (stem cells) to proliferate and repair damaged fibers, making it specifically targeted at exercise-induced hypertrophy.
- Leuprolide is a synthetic GnRH superagonist that, with continuous administration, paradoxically suppresses LH and FSH through receptor desensitization — the opposite effect of pulsatile GnRH. Used medically for prostate cancer, endometriosis, and precocious puberty. In men's health, short-duration use for PCT and testosterone suppression rebound.
- Half-Life
- Native MGF: minutes. PEG-MGF: ~3 days
- ~3 hours (SC/IM), but depot formulations last 1–12 months
- Admin Route
- SubQ, IM
- SubQ, IM
- Research
- —
- —
- Typical Dose
- 200–400 mcg
- 7.5 mg monthly, 22.5 mg 3-monthly, or 45 mg 6-monthly
- Frequency
- 1–2 times per week
- Per depot schedule
- Key Benefits
- Activates muscle satellite cells for repair and growth
- Accelerates recovery from muscle damage
- Synergistic with IGF-1 LR3 (different mechanisms)
- Promotes muscle hypertrophy specifically at exercised muscles
- Faster recovery between training sessions
- Potential for injury repair in connective tissue
- Medical: reduces testosterone in prostate cancer
- Medical: suppresses estrogen in endometriosis and uterine fibroids
- Medical: delays precocious puberty
- Research: testosterone rebound effect after short course
- Transgender care: hormone suppression in adolescents
- Research: hormonal re-sensitization protocols
- Side Effects
- Muscle soreness (satellite cell activation)
- Injection site irritation
- Hypoglycemia risk (modest, less than IGF-1 LR3)
- Hot flashes (with testosterone suppression)
- Decreased libido and erectile dysfunction
- Initial testosterone flare (first 1–2 weeks)
- Bone density loss with long-term use
- +3 more
- Stacks With
- —
- —